Medifast
MED
124 hedge funds and large institutions have $111M invested in Medifast in 2025 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 41 reducing their positions, and 24 closing their positions.
129% more call options, than puts
Call options by funds: $7.34M | Put options by funds: $3.2M
10% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 41
4% less funds holding
Funds holding: 129 → 124 (-5)
6.21% less ownership
Funds ownership: 81.56% → 75.35% (-6.2%)
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
29% less capital invested
Capital invested by funds: $157M → $111M (-$46.1M)
Top Buyers
Top Sellers
| 1 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$5.2M |
| 2 |
Goldman Sachs
New York
|
-$2.71M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.23M |
| 4 |
ZDA
Zweig-DiMenna Associates
New York
|
-$1.98M |
| 5 |
Jane Street
New York
|
-$1.67M |
MED Hedge Fund Activity: Q1 2025 in Review
124 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Medifast (MED) for Q1 2025, worth a combined $111M — down 29% from $157M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of MED and 20 opened new positions — a net loss of 4 holders — while 41 trimmed existing stakes and 37 added.
The largest buyer was Charles Schwab, adding an estimated $2.27M. The largest seller was Hotchkis & Wiley Capital Management, exiting entirely with an estimated $5.2M sold.
- 124 institutional investors held Medifast (MED) as of Q1 2025, down from 129 in Q4 2024.
- Funds reported $111M of Medifast stock for Q1 2025, down 29% quarter-over-quarter.
- 20 funds opened new Medifast positions in Q1 2025 and 24 closed out, a net change of -4 holders.
- The largest Medifast buyer in Q1 2025 was Charles Schwab, an estimated $2.27M added.
- The largest Medifast seller in Q1 2025 was Hotchkis & Wiley Capital Management, an estimated $5.2M sold.
Based on aggregated 13F filings for Q1 2025.